{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T05:21:49Z","timestamp":1792819309766,"version":"4.5.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:00:00Z","timestamp":1778803200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100025236","name":"Australasian Gastro-Intestinal Trials Group","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100025236","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ejca.2026.116781","type":"journal-article","created":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T06:52:43Z","timestamp":1778309563000},"page":"116781","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["[177Lu]Lu-DOTATATE PRRT and CAPTEM chemotherapy for pancreas and small bowel neuroendocrine tumours: The AGITG CONTROL NETS Multi-centre randomized trial"],"prefix":"10.1016","volume":"241","author":[{"given":"David L.","family":"Chan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9028-8682","authenticated-orcid":false,"given":"Katrin Marie","family":"Sjoquist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David Turner","family":"Ransom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9523-4333","authenticated-orcid":false,"given":"David","family":"Wyld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1886-4280","authenticated-orcid":false,"given":"Kate","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val","family":"Gebski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Murray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew Ddembe","family":"Kiberu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2562-7806","authenticated-orcid":false,"given":"Matthew E.","family":"Burge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-2105-4394","authenticated-orcid":false,"given":"William","family":"Macdonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Roach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Pattison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Butler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy Jay","family":"Price","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0593-2662","authenticated-orcid":false,"given":"Michael","family":"Michael","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4358-4910","authenticated-orcid":false,"given":"Benjamin James","family":"Lawrence","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dale L.","family":"Bailey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3913-5960","authenticated-orcid":false,"given":"John","family":"Leyden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Leyden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John Raymond","family":"Zalcberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Harvey","family":"Turner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1738-0316","authenticated-orcid":false,"given":"Nick","family":"Pavlakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2026.116781_bib1","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2017.0589","article-title":"Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States","author":"Dasari","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2026.116781_bib2","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","article-title":"Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group","volume":"27","author":"Rinke","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116781_bib3","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1056\/NEJMoa1316158","article-title":"Lanreotide in metastatic enteropancreatic neuroendocrine tumors","volume":"371","author":"Caplin","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2026.116781_bib4","article-title":"Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors","author":"Chan","year":"2024","journal-title":"N Engl J Med"},{"issue":"10022","key":"10.1016\/j.ejca.2026.116781_bib5","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/S0140-6736(15)00817-X","article-title":"Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study","volume":"387","author":"Yao","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2026.116781_bib6","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1009290","article-title":"Everolimus for advanced pancreatic neuroendocrine tumors","volume":"364","author":"Yao","year":"2011","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.ejca.2026.116781_bib7","doi-asserted-by":"crossref","first-page":"vii124","DOI":"10.1093\/annonc\/mds295","article-title":"Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"23","author":"Oberg","year":"2012","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2026.116781_bib8","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1159\/000443167","article-title":"ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site","volume":"103","author":"Pavel","year":"2016","journal-title":"Neuroendocrinology"},{"issue":"10","key":"10.1016\/j.ejca.2026.116781_bib9","doi-asserted-by":"crossref","first-page":"E398","DOI":"10.1503\/cmaj.160771","article-title":"Principles of diagnosis and management of neuroendocrine tumours","volume":"189","author":"Raphael","year":"2017","journal-title":"Can Med Assoc J"},{"key":"10.1016\/j.ejca.2026.116781_bib10","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1200\/JCO.2007.15.2553","article-title":"Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival","volume":"26","author":"Kwekkeboom","year":"2008","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2026.116781_bib11","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 Trial of 177 Lu-Dotatate for Midgut Neuroendocrine Tumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"N Engl J Med"},{"issue":"10446","key":"10.1016\/j.ejca.2026.116781_bib12","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1016\/S0140-6736(24)00701-3","volume":"403","author":"Singh","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2026.116781_bib13","first-page":"1919","article-title":"Metronomic capecitabine in gastroenteropancreatic neuroendrocrine tumors: a suitable regimen and review of the literature","volume":"7","author":"Bongiovanni","year":"2014","journal-title":"OncoTargets Ther"},{"issue":"3","key":"10.1016\/j.ejca.2026.116781_bib14","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s00280-012-2055-z","article-title":"Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience","volume":"71","author":"Fine","year":"2013","journal-title":"Cancer Chemother Pharm"},{"issue":"7","key":"10.1016\/j.ejca.2026.116781_bib15","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1200\/JCO.22.01013","article-title":"Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors (ECOG-ACRIN E2211)","volume":"41","author":"Kunz","year":"2023","journal-title":"J Clin Oncol J Am Soc Clin Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2026.116781_bib16","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1053\/j.seminoncol.2014.09.013","article-title":"Altering the response to radiation: sensitizers and protectors","volume":"41","author":"Citrin","year":"2014","journal-title":"Semin Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2026.116781_bib17","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1159\/000434723","article-title":"Pancreatic Neuroendocrine Tumor Control: Durable Objective Response to Combination177Lu-Octreotate-Capecitabine-Temozolomide Radiopeptide Chemotherapy","volume":"103","author":"Claringbold","year":"2016","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.ejca.2026.116781_bib18","unstructured":"Van der Zwan W., Wyld D., Brabander T., Teunissen J., Kam B., MacFarlane D., et al. A Randomized Controlled Study Comparing Treatment of Gastro-Entero-Pancreatic Neuroendocrine Tumors (GEPNET) with 177Lu-DOTATATE Alone and in Combination with Capecitabine. In: Proceedings of ENETS 2018 [Internet]. Barcelona, Spain; [cited 2021 Mar 12]. p. Abst #2286. Available from: https:\/\/www.enets.org\/a-randomized-controlled-study-comparing-treatment-of-gastro-entero-pancreatic-neuroendocrine-tumors-gepnet-with-177lu-dotatate-alone-and-in-combination-with-capecitabine.html."},{"issue":"2","key":"10.1016\/j.ejca.2026.116781_bib19","doi-asserted-by":"crossref","first-page":"238","DOI":"10.2967\/jnumed.124.268617","article-title":"177Lu-DOTATATE Plus Capecitabine Versus 177Lu-DOTATATE Alone in Patients with Advanced Grade 1\/2 Gastroenteropancreatic Neuroendocrine Tumors (LuCAP): A Randomized, Phase 2 Trial","volume":"66","author":"Satapathy","year":"2025","journal-title":"J Nucl Med Publ Soc Nucl Med"},{"issue":"2","key":"10.1016\/j.ejca.2026.116781_bib20","first-page":"228","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer Oxf Engl 1990"},{"issue":"2","key":"10.1016\/j.ejca.2026.116781_bib21","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1002\/cncr.25425","article-title":"First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas","volume":"117","author":"Strosberg","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2026.116781_bib22","doi-asserted-by":"crossref","first-page":"S954","DOI":"10.1016\/j.annonc.2022.07.1013","article-title":"887O First multicentric randomized phase II trial investigating the antitumor efficacy of peptide receptor radionucleide therapy with 177Lutetium-Octreotate (OCLU) in unresectable progressive neuroendocrine pancreatic tumor: Results of the OCLURANDOM trial","volume":"33","author":"Baudin","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2026.116781_bib23","first-page":"253","article-title":"A multicenter phase 2 randomized controlled trial comparing 177Lu-Dotatate and capecitabine combination treatment with 177Lu-Dotatate in neuroendocrine tumor patients","author":"Becx","year":"2024","journal-title":"EANM"},{"key":"10.1016\/j.ejca.2026.116781_bib24","article-title":"Peptide receptor chemoradionuclide therapy for neuroendocrine neoplasms: A systematic review","author":"Chan","year":"2023","journal-title":"J Neuroendocr"},{"issue":"3","key":"10.1016\/j.ejca.2026.116781_bib25","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1097\/RLU.0000000000005006","article-title":"Radiosensitizing Favors Response to Peptide Receptor Radionuclide Therapy in Patients With Highly Proliferative Neuroendocrine Malignancies: Preliminary Evidence From a Clinical Pilot Study","volume":"49","author":"Trautwein","year":"2024","journal-title":"Clin Nucl Med"},{"issue":"9","key":"10.1016\/j.ejca.2026.116781_bib26","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1007\/s00259-019-04389-2","article-title":"Characteristics and outcomes of therapy-related myeloid neoplasms after peptide receptor radionuclide\/chemoradionuclide therapy (PRRT\/PRCRT) for metastatic neuroendocrine neoplasia: a single-institution series","volume":"46","author":"Goncalves","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"7","key":"10.1016\/j.ejca.2026.116781_bib27","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1001\/jamaoncol.2020.0078","article-title":"Assessment of Therapy-Related Myeloid Neoplasms in Patients With Neuroendocrine Tumors After Peptide Receptor Radionuclide Therapy: A Systematic Review","volume":"6","author":"Sonbol","year":"2020","journal-title":"JAMA Oncol"},{"issue":"4_","key":"10.1016\/j.ejca.2026.116781_bib28","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1200\/JCO.2022.40.4_suppl.513","article-title":"Risk of myelodysplastic syndrome\/acute leukemia with sequential capecitabine\/temozolomide and177 Lu-dotatate","volume":"40","author":"Al-Toubah","year":"2022","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2026.116781_bib29","doi-asserted-by":"crossref","first-page":"29","DOI":"10.6004\/jnccn.2021.7017","article-title":"Efficacy and Toxicity Analysis of Capecitabine and Temozolomide in Neuroendocrine Neoplasms","volume":"20","author":"Al-Toubah","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.ejca.2026.116781_bib30","article-title":"High metabolic tumour volume on FDG PET predicts poor survival from neuroendocrine neoplasms","author":"Chan","year":"2019","journal-title":"Neuroendocrinology"},{"issue":"10","key":"10.1016\/j.ejca.2026.116781_bib31","doi-asserted-by":"crossref","first-page":"3260","DOI":"10.1007\/s00259-021-05236-z","article-title":"Combined use of 177Lu-DOTATATE and metronomic capecitabine (Lu-X) in FDG-positive gastro-entero-pancreatic neuroendocrine tumors","volume":"48","author":"Nicolini","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"10","key":"10.1016\/j.ejca.2026.116781_bib32","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.2967\/jnumed.124.267982","article-title":"Dual Somatostatin Receptor\/18 F-FDG PET\/CT imaging in patients with well-differentiated, Grade 2 and 3 gastroenteropancreatic neuroendocrine tumors","volume":"65","author":"Metser","year":"2024","journal-title":"J Nucl Med"},{"issue":"4","key":"10.1016\/j.ejca.2026.116781_bib33","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/s41416-022-02061-5","article-title":"Dual [68Ga]DOTATATE and [18F]FDG PET\/CT in patients with metastatic gastroenteropancreatic neuroendocrine neoplasms: a multicentre validation of the NETPET score","volume":"128","author":"Chan","year":"2023","journal-title":"Br J Cancer"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926005629?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926005629?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:26:41Z","timestamp":1780360001000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804926005629"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":33,"alternative-id":["S0959804926005629"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116781","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"[177Lu]Lu-DOTATATE PRRT and CAPTEM chemotherapy for pancreas and small bowel neuroendocrine tumours: The AGITG CONTROL NETS Multi-centre randomized trial","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116781","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"116781"}}